Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002296 · ClinicalTrials.gov registry record · NA
The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease
A NA study, sponsored by Newport Pharmaceuticals International.
- Completed
- Registry status
- NA
- Development phase
NCT00002296 is a NA study that has completed, run by Newport Pharmaceuticals International.
The verdict
NCT00002296, a NA study, has completed, sponsored by Newport Pharmaceuticals International.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of Isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunological parameters: * Increase in natural killer (NK) cell activity. * Increase in total T-cells (OKT-11). * Increases in absolute number and percentage of T-helper cells (OKT-4).
Interventions
- DRUG Inosine pranobex
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002296
The ClinicalTrials.gov registry entry for NCT00002296 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Newport Pharmaceuticals International, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inosine pranobex is the first listed.
NCT00002296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002296 about?
NCT00002296 is a clinical study titled "The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease". The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of Isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of ...
What is the current status of trial NCT00002296?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002296?
The interventions under investigation include: Inosine pranobex (DRUG).
Who is sponsoring clinical trial NCT00002296?
This trial is sponsored by Newport Pharmaceuticals International, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.